Business
Qilian International Holding Group Limited Announces Inclusion of 16 Products into China's National Reimbursement Drugs List
Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and
About this update from Bgm Group Ltd.
[{"type":"text","content":"Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections. In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China. National Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China. The National Essential Medicines List is one of the core contents of the essential medicines system. The system requires that all government-run primary health care institutions be equipped with essential medicines merely and on the respective lists of each province. China’s National Healthcare Security Administration has added 119 products to the National Reimbursement Drugs List effective from March 2021. The list also includes some key products produced by foreign pharmaceutical companies, such as Novartis’ blockbuster inflammation drug Cosentyx, and Israeli firm Teva Pharmaceuticals’ Austedo for treatment of involuntary movements of Huntington’s disease in adults. Inclusion into the list could potentially boost demand for these drugs, as patients will be reimbursed for a significant portion of the costs of purchasing these listed drugs. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, “We are excited to have 16 of our products included in the National Reimbursement Drugs List and 10 out of these 16 products also included in the National Essential Medicines List in China. This means that our products may benefit from being included on such list and their market share grow consequently.” About Qilian International Holding Group Limited Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sau...